5 Costly Mistakes
OTC Companies Make
(And How to Avoid Them)
18+ years of straight-talk advice for development-stage and OTC Market executives — distilled into one practical guide.
- Why treating investor relations as a fundraising tool is quietly killing your raises
- The funding structures most development-stage companies pursue — and why they backfire
- What your communications are telling investors even when you're not talking
- The compliance gaps quietly putting OTC companies at serious risk
- Why scaling too fast destroys more companies than competition ever does
Send Me the Free Guide
Enter your details below and we'll send it directly to your inbox.
✓
You're In.
Your guide is ready to download now.
Open the Guide →Opens in a new tab — use the download icon in your browser to save.
Questions? info@ajenewatsonllc.com
18+ No spam. No pitch. Straight talk from someone who's been in this market for 18+ years.